+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Latin America and Middle East & Africa (LAMEA) Silent Heart Attack Market 2020-2026

  • PDF Icon


  • August 2020
  • Region: Africa, Latin America, Middle East
  • Orion Market Research Private Limited
  • ID: 5148048
Latin America and Middle East & Africa (LAMEA) Silent Heart Attack Market Size, Share & Trends Analysis Report by Diagnosis (Electrocardiography (ECG), MRI, Computed Tomography (CT Scan), Echocardiography, and Others), by Treatment (Medication and Surgery), and by End-User (Hospitals & Clinics and Ambulatory Surgical Centers) and Forecast, 2020-2026.

LAMEA silent heart attack market is estimated to grow at a CAGR of around 5.4% during the forecast period. Rising incidence and prevalence rate of CVD, CHD, and other heart conditions are creating the demand for the diagnosis and treatment of silent heart attacks in the LAMEA region. As per the data published by the Ministry of Health and Prevention (MOHAP), in September 2019, the prevalence of hypertension in UAE has recorded 28.8%. This represents a significant number of hypertensive patients in the country. Likewise, rising hypertension among patients in South Africa is expected to boost the adoption of diagnosis and treatment procedures to reduce the possibility of occurrence of severe conditions, including heart attack. The prevalence of hypertension is rising in Latin American countries owing to the significant rise in obese and overweight population, sedentary lifestyle coupled with the excessive consumption of alcohol and tobacco. As per the survey conducted by the Ministry of Health (Brazil), the obesity rate in Brazil was increased from 11.8% to 19.8% between 2006 and 2018.

LAMEA silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Surgery is most commonly required to increase blood flow through a blocked artery. Therefore, angioplasty and bypass surgery are significantly used for the management of blocked arteries and improve blood flow to the heart.

The companies which are contributing to the growth of the LAMEA silent heart attack market include AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Pfizer Inc., Terumo Corp., and Teva Pharmaceutical Industries Ltd. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of the LAMEA silent heart attack market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation:

1. LAMEA Silent Heart Attack Market Research and Analysis by Diagnosis
2. LAMEA Silent Heart Attack Market Research and Analysis by Treatment
3. LAMEA Silent Heart Attack Market Research and Analysis by End-User

The Report Covers:
  • Comprehensive research methodology of the LAMEA silent heart attack market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the LAMEA silent heart attack market.
  • Insights about market determinants which are stimulating the LAMEA silent heart attack market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. LAMEA Silent Heart Attack Market by Diagnosis
5.1.1. Electrocardiography (ECG)
5.1.2. Magnetic Resonance Imaging (MRI)
5.1.3. Computed Tomography (CT Scan)
5.1.4. Echocardiography
5.1.5. Others (Blood Test)
5.2. LAMEA Silent Heart Attack Market by Treatment
5.2.1. Medication
5.2.2. Surgery Angioplasty Bypass Surgery Heart Transplant
5.3. LAMEA Silent Heart Attack Market by End-Users
5.3.1. Hospital & Clinics
5.3.2. Ambulatory Surgical Centers
6. Regional Analysis
6.1. Brazil
6.2. Argentina
6.3. UAE
6.4. Kenya
6.5. South Africa
6.6. Nigeria
6.7. Rest of LAMEA
7. Company Profiles
7.1. Astellas Pharma Inc.
7.2. AstraZeneca PLC
7.3. Bayer AG
7.4. Boehringer Ingelheim GmbH
7.5. Boston Scientific Corp.
7.6. F. Hoffmann-La Roche Ltd.
7.7. GlaxoSmithKline Plc
7.8. Medtronic PLC
7.9. Novartis AG
7.10. Pfizer Inc.
7.11. Siemens AG
7.12. Takeda Pharmaceutical Co. Ltd.
7.13. Terumo Corp.
7.14. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corp.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Medtronic PLC
  • Novartis AG
  • Pfizer Inc.
  • Siemens AG
  • Takeda Pharmaceutical Co. Ltd.
  • Terumo Corp.
  • Teva Pharmaceutical Industries Ltd.